Thirty-six hospitalized patients with circulating antibody to Pseudomonas pseudomallei were Classified as having either clinical or subclinical meioidosis after full clinical examinations and supplementary radiological and culture investigations. Qualitative estimations of immunoglobulin M (IgM) antibody response were determined by complement fixation, indirect hemagglutination, and immunofluorescence, and the estimations were correlated with the clinical findings in each patient. An attempt was made to appraise the importance of IgM antibody, as determined by each test, in establishing the diagnosis of clinical melioidosis. Results obtained from serological tests were of no value in differentiating between active and latent infections. However, the IgM-immunofluorescent test appeared to be relevant to the diagnosis of clinical melioidosis, since the presence and absence of IgM-immunofluorescent antibody bore a close relation to clinical and subclinical disease, respectively. Surveillance studies indicated that the IgMimmunofluorescent test may also be of value in monitoring the activity and treatment of the infection, since the results of the test were generally negative 3 to 6 months after administration of chemotherapy appropriate for melioidosis.
The serological diagnosis of clinical melioidosis is presently established by demonstrating rising antibody titers to Pseudomonaspseudomallei with modifications of the complement fixation (CF) test of Nigg and Johnston (9) and the indirect hemagglutination (IHA) test of leri (4) . However, in a significant number of instances, a stable high titer is present by the time the patient is first seen by a physician. Since (6) . However, since diagnosis of this disease relies entirely on either isolation of P. pseudomallei or on serological techniques, it is essential that the antibody status of the patient be clearly defined, since cultures for P. pseudomallei from clinical specimens are frequently negative and melioidosis mimics many other disease processes.
The differentiation of various infectious diseases into active and past infections has been elucidated by the presence or absence in serum of specific immunoglobulin M (IgM) antibody, because IgM is usually formed early in response to infection, and IgG is formed later. A simple, rapid method, applicable to small diagnostic laboratories, for estimating IgM fraction is mild treatment of the serum with a sulfhydryl compound which splits the IgM fraction into 6 to 7S subunits. In serum treated in this manner, IgM antibodies are inactivated, whereas the serological behavior of IgG is unaffected (8) . Preliminary studies have also suggested that detection by immunofluorescence of IgM antibody specific to P. pseudomallei may be a useful procedure in the diagnosis of clinical melioidosis (la Demonstration of antibodies to P. pseudomallei. Sera were tested for antibodies specific to P. pseudomallei by CF, IHA, and indirect fluorescentantibody (IFA) methods. The CF test was carried out by using a microtitration adaptation of the methods of Laws (7), and the IHA test was performed by using a microtitration adaptation of the technique of Jones and Hambie (5 
RESULTS
Of the 36 patients examined, 6 felt entirely well and free from symptoms of melioidosis. Another seven patients showed mild symptoms but were considered by the examining physicians not to be suffering from active infection and were classified as having subclinical melioidosis. Of the remaining 23 patients, 5 were classified as having acute, 10 as having subacute, and 8 as having chronic forms of melioidosis. The symptoms most frequently encountered were anorexia, weight loss, cough, fever, night sweats, tachypnea, and hepatomegaly. P. pseudomallei was recovered from the cultures from 16 of these patients. Abnormal radiographic pictures were seen in 11 of 36 patients, but the X-ray films from only 7 patients showed pulmonary involvement consistent with meioidosis. Patients diagnosed as having clinical melioidosis were treated with appropriate chemotherapy for periods ranging from 1 to 12 months. The clinical findings for six of these patients have been described more fully elsewhere (2) .
As determined from the initial sera collected from the 36 patients, the serological reactions were positive in all tests on untreated sera except for tests on the sera from two patients in which the CF and IFA tests gave positive reactions but the IHA test failed to detect specific antibody. Sera from these patients were collected while they were suffering from bacteremia caused by P. pseudomallei.
An antibody reduction ratio (ARR) for each test was determined by dividing the reciprocal of the antibody titer of serum treated with dithiothreitol by the reciprocal of the antibody titer obtained from the sample of untreated serum. Hence, the detection of IgG would only be expressed as an ARR equivalent to 1; an ARR of 0 would reflect the presence of IgM alone, and an ARR of 0.5 would indicate a twofold difference in antibody titer between dithiothreitoltreated serum and untreated serum. The ARR calculated for serum samples by CF and IHA were compared with the results of the IgM-IFA test (Table 1) .
After reductive cleavage, a significant decrease in antibody titer (ARR, <0.25) was noted by CF in 31 sera, suggesting that IgM was the predominant class of antibody detected by this method. Except in sera from two patients, the IHA test was found to measure IgM antibody almost exclusively in that all specific antibody was inactivated by dithiothreitol, resulting in titers of 1:5 or less. Although CF and IHA detected significant levels of specific IgM antibody, there appeared to be no correlation among initial antibody titers determined by these tests, ARR, and disease status in the 36 patients under study ( Table 2) .
The IgM-IFA test was positive (titer, 21:10) for untreated sera from 25 of the 36 patients but gave negative reactions in all 36 sera treated with dithiothreitol. The sera from all 23 patients with clinically active melioidosis gave positive reactions in the IgM-IFA test. Sera from the 16 patients with positive cultures showed high specific IgM-IFA titers ranging from 1:40 to 1:640, whereas the lowest IgM-IFA titer obtained from sera from the remaining 7 patients with clinical melioidosis was 1:40. Of the 13 patients with subclinical melioidosis, the sera from only 2 patients gave positive IgM-IFA test results, and the titers were found to be 1:20 or less (Table 2) . Specific antibody, detected by IHA over various time periods after diagnosis and treatment of the 23 cases of clinical melioidosis, persisted in all patients for the first 6 months, and only three patients after that period were found to be devoid of IHA antibody after 2 years of surveillance. In contrast, sera from 9 patients were negative (titer, <1:10) for IgM-IFA antibody within 3 months, and 16 patients showed negative reactions within 6 months. In the sera from five patients, IgM-IFA antibody persisted for 1 year, whereas sera from two patients remained reactive at low titers for 2 years. Despite high dosage, long-term chemotherapy, relapse of infection, proven by positive cultures, occurred in three patients, all of whom had persistent low titers (1:10 to 1:20) of IgM-IFA antibody. Recrudescence of disease was reflected by significant changes in titer (1:80 to 1:320) in the IgM-IFA test.
Of the sera collected from 84 hospitalized patients, all were negative by the IHA test for P. pseudomallei and were subsequently tested with the IgM-IFA test to determine if a false-positive test may have resulted from various unrelated illnesses. All 84 sera were negative in this test. DISCUSSION It was thought that indirect demonstration of specific IgM by CF or IHA would help to differentiate between active and latent infections with P. pseudomallei. However, the present study has shown that information obtained from serological results after treatment of sera with dithiothreitol was of no value and bore no better relation to clinical findings than results from serological tests on untreated sera. Consequently, it can be concluded that CF or IHA titer does not reflect the stage of infection nor is a measure of activity.
Preliminary studies (la) suggested that detection of specific IgM antibodies by immunofluorescence may be helpful in assessing active infection with P. pseudomallei. Results However, additional assessment of a larger number of cases of melioidosis is necessary before these findings can be accepted as definitive diagnostic criteria for determining infection. The IgM-IFA test has been performed routinely for more than 1 year at the Australian Department of Health, Pathology Laboratory, which is the reference center for serological studies of melioidosis in Northern Australia, and the test has been particularly beneficial in establishing a diagnosis of clinical melioidosis when the organism cannot be recovered from clinical material.
